دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn’s Disease
Emily C L Wong, BHSc, Parambir S Dulai, MD, John K Marshall, MD, MSc, Vipul Jairath, MD, PhD, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH
doi : 10.1093/ibd/izac168
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1015–1023
There is a need to better understand the positioning of biologic therapies for long-term outcomes in biologic-naïve Crohn’s disease (CD). We assessed the comparative effectiveness of infliximab and ustekinumab among induction responders for 1-year outcomes.
Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn’s Disease
Romain Ferru-Clément, PhD, Gabrielle Boucher, MSc, Anik Forest, MSc, Bertrand Bouchard, MSc, Alain Bitton, MD, Sylvie Lesage, PhD, Phil Schumm, PhD, Mark Lazarev, MD, Steve Brant, MD, Richard H Duerr, MD, Dermot P B McGovern, MD PhD, Mark Silverberg, MD PhD, Judy H Cho, MD, NIDDK IBD Genetics Consortium, iGenoMed Consortium, Ashwin Ananthakrishnan, MD, Ramnik J Xavier, MD, John D Rioux, PhD, Christine Des Rosiers, PhD
doi : 10.1093/ibd/izac281
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1024–1037,
There is an unmet medical need for biomarkers that capture host and environmental contributions in inflammatory bowel diseases (IBDs). This study aimed at testing the potential of circulating lipids as disease classifiers given their major roles in inflammation.
Ustekinumab Tissue and Serum Levels in Patients With Crohn’s Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction
Elisa Proietti, PhD, Renske W M Pauwels, MD, PhD, Christien J van der Woude, MD, PhD, Michael Doukas, MD, PhD, Lindsey Oudijk, MD, PhD, Maikel P Peppelenbosch, PhD, Ursula Grohmann, PhD, Marie-Rose B S Crombag, PharmD, PhD, Annemarie C de Vries, MD, PhD, Gwenny M Fuhler, PhD
doi : 10.1093/ibd/izac169
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1038–1046
Ustekinumab (UST), which targets p40/interleukin (IL)-23 and IL-12, is an effective treatment for Crohn’s disease (CD). Therapeutic drug monitoring may optimize UST posology. The aim of this study was to investigate UST and IL-23 serum and tissue concentrations in relation to mucosal inflammation and treatment response at an early time point.
Risks of Melanoma and Nonmelanoma Skin Cancers Pre– and Post–Inflammatory Bowel Disease Diagnosis
Mariam Narous, MD, Zoann Nugent, PhD, Harminder Singh, MD, Charles N Bernstein, MD
doi : 10.1093/ibd/izac171
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1047–1056
We compared risks of nonmelanoma skin cancers (NMSCs) and melanoma preceding and following a diagnosis of inflammatory bowel disease (IBD) and to evaluate the effect of thiopurines and anti-tumor necrosis factor α (anti-TNF-α) on skin cancer risk in IBD.
Occurrence and Clinical Impact of Eosinophilic Esophagitis in a Large Cohort of Children With Inflammatory Bowel Disease
Marina Aloi, MD, PhD, Giulia D’Arcangelo, MD, Danilo Rossetti, MD, Simone Bucherini, MD, Enrico Felici, MD, Claudio Romano, MD, Massimo Martinelli, MD, Valeria Dipasquale, MD, Paolo Lionetti, MD, Salvatore Oliva, MD, PhD
doi : 10.1093/ibd/izac172
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1057–1064
Scarce data have investigated the association between pediatric inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE). We, therefore, aimed to describe the epidemiology and the possible peculiar phenotype and natural history of such an association.
Young Adult Male Patients With Childhood-onset IBD Have Increased Risks of Compromised Cortical and Trabecular Bone Microstructures
Gudmundur Vignir Sigurdsson, MD, Susanne Schmidt, MD, PhD, Dan Mellström, MD, Claes Ohlsson, MD, Robert Saalman, MD, Mattias Lorentzon, MD
doi : 10.1093/ibd/izac181
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1065–1072
Young adults with childhood-onset inflammatory bowel disease (IBD) have increased risks of low areal bone mineral density and low skeletal muscle mass. Volumetric BMD (vBMD), bone geometry and microstructures, in addition to possible associations with skeletal muscle index (SMI) and physical exercise have been scarcely studied in this patient group.
Aeroallergen-related Diseases Predate the Diagnosis of Inflammatory Bowel Disease
Namarik Alenezy, MD, Zoann Nugent, PhD, Sari Herman, MD, Karver Zaborniak, MD, Clare D Ramsey, MD, Charles N Bernstein, MD
doi : 10.1093/ibd/izac184
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1073–1079
This study aimed to determine whether having a diagnosis of asthma or allergic rhinitis (AR) increased the risk of being diagnosed with inflammatory bowel disease (IBD) and whether there was increased incidence of these diseases after a diagnosis of IBD.
Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease
Rose Vaughan, MBBS, Elise Murphy, MClinPharm, Michelle Nalder, MClinPharm, Robert N Gibson, MD, Zaid Ardalan, MBChB, Alex Boussioutas, PhD, Britt Christensen, PhD
doi : 10.1093/ibd/izac186
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1080–1088
Mucosal healing improves clinical outcomes in patients with inflammatory bowel disease (IBD) and is associated with higher infliximab trough levels (ITLs). Transmural healing, assessed by intestinal ultrasound (IUS), is emerging as an objective target in Crohn’s disease (CD) and ulcerative colitis (UC). This study explores the correlation between maintenance ITLs and sonographic transmural healing.
Validating the Simplified Endoscopic Mucosal Assessment for Crohn’s Disease: A Novel Method for Assessing Disease Activity
Jeremy Adler, MD, MSc, Richard B Colletti, MD, Lenore Noonan, RT, Tyler M Berzin, MD, Adam S Cheifetz, MD, Laurie S Conklin, MD, Timothy C Hoops, MD, Christopher S Huang, MD, Blair Lewis, MD, Daniel S Mishkin, MD, Kim Hung Lo, PhD, Yongling Xiao, PhD, Sheri Volger, PhD, RDN
doi : 10.1093/ibd/izac183
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1089–1097
To demonstrate treatment efficacy in Crohn’s disease (CD), regulatory authorities require that trials include an endoscopic remission/response end point; however, standardized endoscopic assessment of disease activity, such as the Simple Endoscopic Score for Crohn’s Disease (SES-CD), is not typically recorded by clinicians in practice or outside of clinical trials.
Peripartum Infections Among Women With Inflammatory Bowel Disease
Bar Narkis, MD, Eran Hadar, MD, Shiri Barbash-Hazan, MD, Ohad Houri, MD, Vardit Shay, M.Sc, Jacob E Ollech, MD, Henit Yanai, MD, Iris Dotan, MD, Irit Avni-Biron, MD
doi : 10.1093/ibd/izac185
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1098–1104
Pregnant patients with inflammatory bowel diseases (IBDs) are frequently treated with immunomodulatory agents and may be at increased risk of adverse outcomes, including peripartum infections. We sought to examine the risk for peripartum infections in patients with IBD compared with control subjects and identify potential risk factors associated with peripartum infections in these patients.
A Novel Probiotic Combination Ameliorates Crohn’s Disease–Like Ileitis by Increasing Short-Chain Fatty Acid Production and Modulating Essential Adaptive Immune Pathways
Luca Di Martino, PhD, Abdullah Osme, MD, Mahmoud Ghannoum, PhD, Fabio Cominelli, MD, PhD
doi : 10.1093/ibd/izac284
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1105–1117,
Crohn’s disease (CD) represents a significant public health challenge. We identified a combination of beneficial probiotic strains (Saccharomyces boulardii, Lactobacillus rhamnosus, Lactobacillus acidophilus, and Bifidobacterium breve) and amylase that may antagonize elevated bacterial pathogens in the inflamed gut.
Microbial Dynamics in Newly Diagnosed and Treatment Naïve IBD Patients in the Mediterranean
Philipp Rausch, PhD, Sarah Ellul, MD, Anthea Pisani, MD, Corinna Bang, PhD, Trevor Tabone, MD, Claire Marantidis Cordina, MD, Graziella Zahra, MD, Andre Franke, PhD, Pierre Ellul, MD
doi : 10.1093/ibd/izad004
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1118–1132,
Microbial communities have long been suspected to influence inflammatory processes in the gastrointestinal tract of patients with inflammatory bowel disease. However, these effects are often influenced by treatments and can rarely be analyzed in treatment-naïve onset cases.
Inhibition of Soluble Stem Cell Factor Promotes Intestinal Mucosal Repair
Vicky Garcia-Hernandez, PhD, Arturo Raya-Sandino, PhD, Veronica Azcutia, PhD, Jael Miranda, PhD, Matthias Kelm, MD, Sven Flemming, MD, Dorothee Birkl, MD, Miguel Quiros, PhD, Jennifer C Brazil, PhD, Charles A Parkos, MD, PhD, Asma Nusrat, MD
doi : 10.1093/ibd/izad003
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1133–1144
Incidences of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, are escalating worldwide and can be considered a global public health problem. Given that the gold standard approach to IBD therapeutics focuses on reducing the severity of symptoms, there is an urgent unmet need to develop alternative therapies that halt not only inflammatory processes but also promote mucosal repair.
Endoscopic Stenting in Crohn’s Disease-related Strictures: A Systematic Review and Meta-analysis of Outcomes
Saurabh Chandan, MD, Banreet S Dhindsa, MD, Shahab R Khan, MBBS, Smit Deliwala, MD, Lena L Kassab, MD, Babu P Mohan, MD, Ojasvini C Chandan, MD, Carme Loras, MD, PhD, Bo Shen, MD, Gursimran S Kochhar, MD
doi : 10.1093/ibd/izac153
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1145–1152
Crohn’s disease (CD) is a chronic progressive condition that is complicated by intestinal or colonic stricture in nearly 30% of cases within 10 years of the initial diagnosis.
The Oral-Gut Axis: Periodontal Diseases and Gastrointestinal Disorders
Gretchen A Lam, DMD, Hala Albarrak, BDS, Cassidy J McColl, MSc, Alaina Pizarro, Harsha Sanaka, Adrian Gomez-Nguyen, PhD, Fabio Cominelli, MD, PhD, Andre Paes Batista da Silva, DDS, Msc, PhD
doi : 10.1093/ibd/izac241
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1153–1164
One of the prospective sequelae of periodontal disease (PD), chronic inflammation of the oral mucosa, is the development of inflammatory gastrointestinal (GI) disorders due to the amplification and expansion of the oral pathobionts.
Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients
Laura Ramos, MD, Miriam Hernández-Porto, PhD, Marta Carrillo-Palau, MD, PhD, Inmaculada Alonso-Abreu, MD, PhD, Cristina Reygosa, MD, Manuel Hernandez-Guerra, MD, PhD
doi : 10.1093/ibd/izac228
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1165–1169
The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn’s Disease
Dotan Yogev, MD, Bram Verstockt, MD, PhD, Axel Dignass, MD, PhD, Gili Focht, MSc, MBA, Ohad Atia, MD, Iris Dotan, MD, PhD, Severine Vermeire, MD, PhD, Dan Turner, MD, PhD
doi : 10.1093/ibd/izac235
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1170–1174
Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn’s Disease
Lauren V Collen, MD
doi : 10.1093/ibd/izad048
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1175–1176
Frail Phenotype in Patients With Inflammatory Bowel Disease
Cong Dai, MD, PhD, Yu-Hong Huang, MD
doi : 10.1093/ibd/izac278
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Page e30
